Insmed, Inc. (NASDAQ:INSM) Shares Sold by Fourth Dimension Wealth LLC

Fourth Dimension Wealth LLC cut its holdings in Insmed, Inc. (NASDAQ:INSM - Free Report) by 59.7% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,622 shares of the biopharmaceutical company's stock after selling 2,399 shares during the quarter. Fourth Dimension Wealth LLC's holdings in Insmed were worth $124,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the business. Principal Securities Inc. increased its holdings in shares of Insmed by 55.5% in the 4th quarter. Principal Securities Inc. now owns 3,139 shares of the biopharmaceutical company's stock valued at $217,000 after acquiring an additional 1,120 shares during the period. Sanctuary Advisors LLC lifted its position in shares of Insmed by 13.7% during the fourth quarter. Sanctuary Advisors LLC now owns 3,861 shares of the biopharmaceutical company's stock valued at $295,000 after buying an additional 464 shares during the last quarter. CIBC Asset Management Inc boosted its holdings in shares of Insmed by 5.6% in the 4th quarter. CIBC Asset Management Inc now owns 4,685 shares of the biopharmaceutical company's stock valued at $323,000 after buying an additional 247 shares in the last quarter. Truist Financial Corp grew its position in shares of Insmed by 3.4% in the 4th quarter. Truist Financial Corp now owns 30,038 shares of the biopharmaceutical company's stock worth $2,074,000 after buying an additional 1,000 shares during the last quarter. Finally, Venturi Wealth Management LLC bought a new position in shares of Insmed during the 4th quarter worth approximately $86,000.

Insider Activity

In other Insmed news, CEO William Lewis sold 6,830 shares of the business's stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $72.57, for a total transaction of $495,653.10. Following the completion of the sale, the chief executive officer now directly owns 233,924 shares in the company, valued at approximately $16,975,864.68. The trade was a 2.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Martina M.D. Flammer sold 9,925 shares of the firm's stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $65.47, for a total value of $649,789.75. Following the completion of the transaction, the insider now owns 86,596 shares in the company, valued at approximately $5,669,440.12. This trade represents a 10.28% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 488,752 shares of company stock worth $43,199,826 in the last quarter. Corporate insiders own 3.00% of the company's stock.

Insmed Price Performance

Shares of Insmed stock traded down $1.05 during trading hours on Wednesday, reaching $104.85. The stock had a trading volume of 3,523,867 shares, compared to its average volume of 2,179,750. The stock's 50 day moving average is $76.19 and its 200 day moving average is $74.95. The company has a current ratio of 5.86, a quick ratio of 5.44 and a debt-to-equity ratio of 11.38. Insmed, Inc. has a twelve month low of $60.40 and a twelve month high of $106.84. The firm has a market capitalization of $19.89 billion, a PE ratio of -17.62 and a beta of 0.80.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). The business had revenue of $92.82 million during the quarter, compared to analyst estimates of $91.63 million. Insmed had a negative return on equity of 446.98% and a negative net margin of 265.93%. The business's revenue for the quarter was up 22.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.06) EPS. Equities analysts expect that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Mizuho raised their target price on shares of Insmed from $96.00 to $110.00 and gave the company an "outperform" rating in a research note on Wednesday, June 11th. Citigroup raised Insmed to a "buy" rating in a research report on Tuesday, June 10th. Wells Fargo & Company upped their target price on Insmed from $107.00 to $119.00 and gave the company an "overweight" rating in a research report on Wednesday, June 11th. UBS Group lowered their price target on Insmed from $110.00 to $109.00 and set a "buy" rating for the company in a report on Friday, May 9th. Finally, HC Wainwright upped their price objective on shares of Insmed from $90.00 to $120.00 and gave the company a "buy" rating in a report on Wednesday, June 11th. One analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $106.80.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.